Maa: Australia
Kieli: englanti
Lähde: Department of Health (Therapeutic Goods Administration)
Propolis dry extract
H C L Manufacturers Pty Ltd
Propolis dry extract
Medicine Listed (Export Only)
Listed (Export Only)
MAREVAN ® M A R E V A N CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING MAREVAN? MAREVAN contains the active ingredient warfarin. MAREVAN is used to prevent blood from excessive clotting or forming harmful clots. For more information, see Section 1. Why am I using MAREVAN? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE MAREVAN? Do not use if you have ever had an allergic reaction to MAREVAN or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use MAREVAN? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with MAREVAN and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE MAREVAN? • Follow your doctor’s directions exactly about how much MAREVAN to take. Different people require different amounts of this medicine, and the dosage is adjusted to suit you. Your doctor will determine how much to take through blood tests. • MAREVAN should be taken at about the same time each day. More instructions can be found in Section 4. How do I use MAREVAN? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING MAREVAN? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using MAREVAN. • If you are going to have surgery, tell the surgeon or anaesthetist that you are taking this medicine. • If you become pregnant while taking this medicine, tell your doctor immediately. • If you are about to have any blood tests, tell your doctor that you are taking this medicine. THINGS YOU SHOULD NOT DO • Do not stop taking your medicine or lower the dosage without checking with your doctor. • There are two brands of w Lue koko asiakirja
AUSTRALIAN PRODUCT INFORMATION MAREVAN ® _warfarin sodium _ 1 NAME OF THE MEDICINE Warfarin sodium 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each MAREVAN tablet contains 1 mg, 3 mg or 5 mg of warfarin sodium as the active ingredient. Excipients of known effect: sugars as lactose and sulfites. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM MAREVAN 1 mg tablets are a flat fawn coloured tablet with bevelled edge, scored and embossed with “M” above and “1” below. MAREVAN 3 mg tablets are flat blue coloured tablet with bevelled edge, scored and embossed with “M” above and “3” below. MAREVAN 5 mg tablets are flat pink coloured tablet with bevelled edge, scored and embossed with “M” above and “5” below. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS MAREVAN is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. MAREVAN is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. MAREVAN is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (TIA, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. MAREVAN is indicated for use as an adjunct in the treatment of coronary occlusion. 4.2 DOSE AND METHOD OF ADMINISTRATION It cannot be emphasised too strongly that treatment of each patient is a highly individualised matter. MAREVAN, a narrow therapeutic range (index) drug, may be affected by factors such as other drugs, dietary Vitamin K and genetic variations in CYP2CP and VKORC1 enzymes. Dosage should be controlled by periodic determinations of International Normalised Ratio (INR) or other suitable coagulation tests and the condition being treated (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION – Administration). The following ranges of INR may be considered for the following listed conditions or procedures; ho Lue koko asiakirja